moatshark My

All holdings

Dexcom

DXCM

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
0
In their latest 13F (Q3 2026)
See who
Value held
$0k
Combined value at quarter end
Last quarter
0 bought
1 sold or trimmed
Price at Q1 ’26 end
$62.79
-5.4% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

-5.4%Q1 ’26
Q1 ’26: -5.4%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

0Q4 ’23
0Q1 ’24
0Q2 ’24
0Q3 ’24
0Q4 ’24
0Q1 ’25
0Q2 ’25
0Q3 ’25
1Q4 ’25
1Q1 ’26
0Q2 ’26
0Q3 ’26
Q4 ’23: 0; Q1 ’24: 0; Q2 ’24: 0; Q3 ’24: 0; Q4 ’24: 0; Q1 ’25: 0; Q2 ’25: 0; Q3 ’25: 0; Q4 ’25: 1; Q1 ’26: 1; Q2 ’26: 0; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Dexcom.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

No manager on this site held it in their latest 13F.

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Dexcom
Bought or soldFiling
15 Oct 2026Brown Michael JonEVP Chief Legal Compliance Off▼ Sold1,700$85.48$145kForm 4
28 Sep 2026Stern SadieEVP Chief People & Culture Off▼ Sold2,565$86.15$221kForm 4
15 Sep 2026Augustinos NicholasDirector▼ Sold6,539$84.04$550kForm 4
15 Sep 2026Brown Michael JonEVP Chief Legal Compliance Off▼ Sold1,700$84.04$143kForm 4
14 Sep 2026Augustinos NicholasDirector▼ Sold1,550$84.02$130kForm 4
10 Sep 2026Sylvain Jereme MEVP, Chief Financal Officer▼ Sold3,638$83.27$303kForm 4
27 Aug 2026Stern SadieEVP Chief People & Culture Off▼ Sold2,565$88.37$227kForm 4
20 Aug 2026Sayer Kevin RExecutive Chair▼ Sold19,308$89.71$1.7mForm 4
20 Aug 2026Sayer Kevin RExecutive Chair▼ Sold7,351$90.78$667kForm 4
20 Aug 2026Sayer Kevin RExecutive Chair▼ Sold97$91.41$9kForm 4
14 Aug 2026Brown Michael JonEVP Chief Legal Compliance Off▼ Sold1,700$91.93$156kForm 4
12 Aug 2026Heller Bridgette PDirector▼ Sold1,012$88.29$89kForm 4
3 Aug 2026Foletta Mark GDirector▼ Sold2,000$85.32$171kForm 4
31 Jul 2026Foletta Mark GDirector▼ Sold2,000$80.00$160kForm 4
20 Jul 2026Sayer Kevin RExecutive Chair▼ Sold26,756$76.32$2.0mForm 4

About the company

Sector
Health care · Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
377m at 23 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$160m2013
$402m2015
$719m2017
$1.5bn2019
$2.4bn2021
$3.6bn2023
$4.7bn2025
2013: $160m; 2014: $259m; 2015: $402m; 2016: $573m; 2017: $719m; 2018: $1.0bn; 2019: $1.5bn; 2020: $1.9bn; 2021: $2.4bn; 2022: $2.9bn; 2023: $3.6bn; 2024: $4.0bn; 2025: $4.7bn
Dexcom revenue and net income by year
YearRevenueNet income
2025$4.7bn$836m
2024$4.0bn$576m
2023$3.6bn$542m
2022$2.9bn$341m
2021$2.4bn$217m
2020$1.9bn$550m
2019$1.5bn$101m
2018$1.0bn−$127m
2017$719m−$50.2m
2016$573m−$65.6m
2015$402m−$57.6m
2014$259m−$22.4m
2013$160m−$29.8m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

Sold out last quarter